Treatment Program for Anemia in AIDS Patients

NCT ID: NCT00002022

Last Updated: 2005-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Cytopenias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epoetin alfa

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

* Life expectancy \< 3 months.
* = or \< grade 4 performance score.
* AIDS-related dementia.
* Uncontrolled hypertension.
* Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

* Life expectancy \< 3 months.
* = or \< grade 4 performance score.
* AIDS-related dementia.
* Uncontrolled hypertension.
* Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

* A clinical diagnosis of AIDS.
* Hematocrit \< 30 percent.
* Endogenous serum erythropoietin level = or \< 500 U/ml.
* A life expectancy = or \> 3 months.
* \> Grade 4 performance score.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

R W Johnson Pharmaceutical Research Institute

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

R W Johnson Pharmaceutical Research Institute

Raritan, New Jersey, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

I88-083

Identifier Type: -

Identifier Source: secondary_id

004G

Identifier Type: -

Identifier Source: org_study_id